Literature DB >> 2788538

Increased serum levels of IgA1-IgG immune complexes and anti-F(ab')2 antibodies in patients with primary IgA nephropathy.

F P Schena1, A Pastore, N Ludovico, R A Sinico, S Benuzzi, V Montinaro.   

Abstract

A solid-phase ELISA was used to detect IgA1 immune complexes (IgA1 ICs) containing IgG and IgM in 38 serum samples from 30 patients with primary IgA nephropathy (IgAN) and 14 subjects with non-IgA chronic glomerulonephritis. A jackfruit lectin, jacalin, was used as the substrate for the selective binding of human IgA1 ICs in serum PEG precipitate (7%). The presence of IgG, A and M antibodies against the F(ab')2 region of IgG was also investigated by the solid-phase ELISA. Six patients were studied during remission and relapse (fever, upper respiratory tract infection and macroheamaturia). The results showed significant increases in serum levels of IgA1 ICs (P less than 0.001) in 39.4% of the IgAN patients, IgA1-IgG ICs (P less than 0.001) in 68.4%, and IgA1-IgM ICs (P less than 0.002) in 10.5% of the patients. A significant increase in IgA1-IgG ICs was observed during relapse (P less than 0.02). Significantly high values of IgG (P less than 0.003) and IgA (P less than 0.001) antibodies directed at the F(ab')2 region of IgG were found. A significant increase in anti F(ab')2 antibodies (class IgA and IgM) was seen in the acute phase of the disease. The data suggest that an increased production of IgA1 ICs occurs in IgAN patients; ICs are mainly IgA1-IgG ICs during relapse. The presence of high serum levels of IgG and IgA antibodies against the F(ab')2 region of IgG indicates that in addition to the multiple anomalies of IgA regulation described in IgAN patients there may be further aberrances.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788538      PMCID: PMC1541932     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Jacalin: an IgA-binding lectin.

Authors:  M C Roque-Barreira; A Campos-Neto
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

2.  The role of IgA and IgG immune complexes in IgA nephropathy.

Authors:  J Egido; J Sancho; F Rivera; L Hernando
Journal:  Nephron       Date:  1984       Impact factor: 2.847

3.  Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity.

Authors:  R Coppo; B Basolo; G Martina; C Rollino; M De Marchi; F Giacchino; G Mazzucco; M Messina; G Piccoli
Journal:  Clin Nephrol       Date:  1982-11       Impact factor: 0.975

4.  Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes.

Authors:  H H Birdsall; M D Lidsky; R D Rossen
Journal:  Arthritis Rheum       Date:  1983-12

5.  Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy.

Authors:  R M Valentijn; J Radl; J J Haaijman; B J Vermeer; J J Weening; R H Kauffmann; M R Daha; L A van Es
Journal:  Kidney Int       Date:  1984-11       Impact factor: 10.612

6.  Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies.

Authors:  C Czerkinsky; W J Koopman; S Jackson; J E Collins; S S Crago; R E Schrohenloher; B A Julian; J H Galla; J Mestecky
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients.

Authors:  G D'Amico; E Imbasciati; G Barbiano Di Belgioioso; S Bertoli; G Fogazzi; F Ferrario; G Fellin; A Ragni; G Colasanti; L Minetti
Journal:  Medicine (Baltimore)       Date:  1985-01       Impact factor: 1.889

8.  The immunochemical characterization of mesangial IgA deposits.

Authors:  J D Lomax-Smith; L A Zabrowarny; G S Howarth; A E Seymour; A J Woodroffe
Journal:  Am J Pathol       Date:  1983-12       Impact factor: 4.307

9.  Presence of circulating macromolecular IgA in patients with hematuria due to primary IgA nephropathy.

Authors:  R M Valentijn; R H Kauffmann; G B de la Rivière; M R Daha; L A Van ES
Journal:  Am J Med       Date:  1983-03       Impact factor: 4.965

10.  Studies of anti-F(ab')2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus.

Authors:  F Silvestris; A D Bankhurst; R P Searles; R C Williams
Journal:  Arthritis Rheum       Date:  1984-12
View more
  14 in total

1.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

Review 2.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

3.  In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells.

Authors:  Takeshi Yanagihara; Rhubell Brown; Stacy Hall; Zina Moldoveanu; Alice Goepfert; Milan Tomana; Bruce A Julian; Jiri Mestecky; Jan Novak
Journal:  Results Immunol       Date:  2012-01-01

Review 4.  Experimental IgA nephropathy: factors influencing IgA-immune complex deposition in the glomerulus.

Authors:  A Chen; C H Wei; W H Lee; C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Hypercomplementemia in adult patients with IgA nephropathy.

Authors:  Kisara Onda; Hiroyuki Ohi; Mariko Tamano; Isao Ohsawa; Michiro Wakabayashi; Satoshi Horikoshi; Teizo Fujita; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

6.  Galactosylation of serum IgA1 O-glycans in celiac disease.

Authors:  Katri Lindfors; Hitoshi Suzuki; Jan Novak; Pekka Collin; Päivi Saavalainen; Lotta L E Koskinen; Markku Mäki; Katri Kaukinen
Journal:  J Clin Immunol       Date:  2010-10-12       Impact factor: 8.317

7.  Abnormal glycosylation of serum IgG in patients with IgA nephropathy.

Authors:  Hideki Homma; Keiichi Tozawa; Takahiro Yasui; Yasunori Itoh; Yutaro Hayashi; Kenjiro Kohri
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

8.  Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy.

Authors:  F P Schena; V Scivittaro; E Ranieri; R Sinico; S Benuzzi; M Di Cillo; L Aventaggiato
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 9.  IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Milan Tomana; Jiri Mestecky
Journal:  Semin Nephrol       Date:  2008-01       Impact factor: 5.299

Review 10.  Pathogenesis of idiopathic IgA nephropathy.

Authors:  D G Williams
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.